The demanding requirements of EU GMP Annex 1 present a major challenge for pharmaceutical manufacturers aiming to produce high-quality, safe medicinal products. Successfully achieving compliance involves a multifaceted approach that encompasses comprehensive contamination control strategies. A cornerstone of this effort is the implementation of rig